Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET

PurposeThe follow-up of glioblastoma patients after radiochemotherapy with conventional MRI can be difficult since reactive alterations to the blood–brain barrier with contrast enhancement may mimic tumour progression (i.e. pseudoprogression, PsP). The aim of this study was to assess the clinical value of O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) PET in the differentiation of PsP and early tumour progression (EP) after radiochemotherapy of glioblastoma.MethodsA group of 22 glioblastoma patients with new contrast-enhancing lesions or lesions showing increased enhancement (>25 %) on standard MRI within the first 12 weeks after completion of radiochemotherapy with concomitant temozolomide (median 7 weeks) were additionally examined using amino acid PET with 18F-FET. Maximum and mean tumour-to-brain ratios (TBRmax, TBRmean) were determined. 18F-FET uptake kinetic parameters (i.e. patterns of time–activity curves, TAC) were also evaluated. Classification as PsP or EP was based on the clinical course (no treatment change at least for 6 months), follow-up MR imaging and/or histopathological findings. Imaging results were also related to overall survival (OS).ResultsPsP was confirmed in 11 of the 22 patients. In patients with PsP, 18F-FET uptake was significantly lower than in patients with EP (TBRmax 1.9 ± 0.4 vs. 2.8 ± 0.5, TBRmean 1.8 ± 0.2 vs. 2.3 ± 0.3; both P < 0.001) and presence of MGMT promoter methylation was significantly more frequent (P = 0.05). Furthermore, a TAC type II or III was more frequently present in patients with EP (P = 0.04). Receiver operating characteristic analysis showed that the optimal 18F-FET TBRmax cut-off value for identifying PsP was 2.3 (sensitivity 100 %, specificity 91 %, accuracy 96 %, AUC 0.94 ± 0.06; P < 0.001). Univariate survival analysis showed that a TBRmax <2.3 predicted a significantly longer OS (median OS 23 vs. 12 months; P = 0.046).Conclusion18F-FET PET may facilitate the diagnosis of PsP following radiochemotherapy of glioblastoma.

[1]  D. Kong,et al.  Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status , 2011, American Journal of Neuroradiology.

[2]  W. Shi,et al.  Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma , 2011, Neurology.

[3]  A. Brandes,et al.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  천기정.  뇌종양 진단을 위한 o-(2-[18F]fluoroethyl)-L-tyrosine PET 개발 , 2003 .

[5]  I. Yang,et al.  Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy. , 2010, Neurosurgery clinics of North America.

[6]  G. Fink,et al.  Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-18F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI , 2012, The Journal of Nuclear Medicine.

[7]  A. Drzezga,et al.  [German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids]. , 2011, Nuklearmedizin. Nuclear medicine.

[8]  Toshinori Hirai,et al.  Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. , 2005, AJNR. American journal of neuroradiology.

[9]  D. Hadizadeh,et al.  Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Karl-Josef Langen,et al.  O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. , 2005, Brain : a journal of neurology.

[11]  Namkug Kim,et al.  Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas. , 2012, Radiology.

[12]  M. J. van den Bent,et al.  Pseudoprogression and pseudoresponse in the treatment of gliomas , 2009, Current opinion in neurology.

[13]  J. Kim,et al.  Posttreatment high-grade glioma: usefulness of peak height position with semiquantitative MR perfusion histogram analysis in an entire contrast-enhanced lesion for predicting volume fraction of recurrence. , 2010, Radiology.

[14]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[15]  John O. Prior,et al.  Performance of 18F-Fluoro-Ethyl-Tyrosine (18F-FET) PET for the Differential Diagnosis of Primary Brain Tumor: A Systematic Review and Metaanalysis , 2012, The Journal of Nuclear Medicine.

[16]  Dieta Brandsma,et al.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.

[17]  J. Menten,et al.  Non-invasive grading of brain tumours using dynamic amino acid PET imaging : does it work for 11C-Methionine? , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  R. Baum,et al.  Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for Glioma Grading: Assessment of Individual Probability of Malignancy , 2011, Clinical nuclear medicine.

[19]  A G Sorensen,et al.  Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma , 2011, American Journal of Neuroradiology.

[20]  H. Herzog,et al.  Role of O-(2-18F-Fluoroethyl)-l-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis , 2012, The Journal of Nuclear Medicine.

[21]  Manish K. Aghi,et al.  New advances that enable identification of glioblastoma recurrence , 2009, Nature Reviews Clinical Oncology.

[22]  J. Mountz,et al.  Brain tumors. , 2012, Seminars in nuclear medicine.

[23]  Jianhui Zhong,et al.  Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. , 2010, Radiology.

[24]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[25]  Y. Yoshii.  Pathological review of late cerebral radionecrosis , 2008, Brain Tumor Pathology.

[26]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[27]  Gereon R Fink,et al.  Role of O-(2-18F-Fluoroethyl)-l-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma , 2013, The Journal of Nuclear Medicine.

[28]  W. Koch,et al.  Positron Emission Tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus Magnetic Resonance Imaging in the Diagnosis of Recurrent Gliomas , 2005, Neurosurgery.

[29]  R. Fimmers,et al.  Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients , 2009, Clinical Cancer Research.

[30]  Thomas Beez,et al.  Diagnostic Performance of 18F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of Glioma , 2013, The Journal of Nuclear Medicine.

[31]  J. Uhm.  Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group , 2010 .

[32]  S. Kim,et al.  Differentiation of Tumor Progression from Pseudoprogression in Patients with Posttreatment Glioblastoma Using Multiparametric Histogram Analysis , 2014, American Journal of Neuroradiology.

[33]  Karl-Josef Langen,et al.  O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. , 2006, Nuclear medicine and biology.

[34]  P. Bartenstein,et al.  Dynamic 18F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients , 2014, The Journal of Nuclear Medicine.

[35]  M Schwaiger,et al.  Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  K. Hamacher,et al.  Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. , 2002, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[37]  G. Fink,et al.  Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-l-tyrosine PET in comparison to MRI , 2012, European Journal of Nuclear Medicine and Molecular Imaging.